Aurora Cannabis (TSE:ACB) Hits New 1-Year Low – Should You Sell?

Shares of Aurora Cannabis Inc. (TSE:ACB) hit a new 52-week low during trading on Wednesday . The stock traded as low as C$5.00 and last traded at C$5.02, with a volume of 888958 shares trading hands. The stock had previously closed at C$5.55.

Analysts Set New Price Targets

ACB has been the subject of several recent analyst reports. ATB Capital decreased their price objective on shares of Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating for the company in a report on Thursday, December 11th. Canaccord Genuity Group set a C$10.00 price objective on Aurora Cannabis and gave the stock a “buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of C$9.25.

Aurora Cannabis Trading Down 7.9%

The company has a quick ratio of 2.48, a current ratio of 3.42 and a debt-to-equity ratio of 18.72. The firm has a market capitalization of C$287.42 million, a price-to-earnings ratio of -5.01 and a beta of 0.56. The business has a 50-day moving average of C$6.19 and a two-hundred day moving average of C$6.67.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 5th. The company reported C($0.91) earnings per share (EPS) for the quarter. The firm had revenue of C$90.37 million for the quarter. Aurora Cannabis had a negative net margin of 22.55% and a negative return on equity of 8.36%. Research analysts predict that Aurora Cannabis Inc. will post -0.22 EPS for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.